Primary Biliary Cholangitis Therapeutics Market Insights : Increase in Research and Development of Primary Biliary Cholangitis Therapeutics is Boosting the Market to Propel USD 1.4 Billion Revenue by 2032

Allied Market Research published a report, titled, "Primary Biliary Cholangitis Therapeutics Market by Drug Type (Primary Drug and Secondary Drug), and Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032" According to the report, the global primary biliary cholangitis therapeutics industry generated $0.68 billion in 2022 and is anticipated to generate $1.36 billion by 2032, witnessing a CAGR of 7.1% from 2023 to 2032.

The growth of the global primary biliary cholangitis therapeutics market is driven by increased awareness of the disease in developing countries, rising demand for corresponding treatments, and expanded research and development efforts. However, challenges such as delayed diagnosis and limited treatment options impede market growth. Conversely, opportunities for market expansion are anticipated through the adoption of key strategies by major industry players and the escalation of clinical trials investigating drugs for primary biliary cholangitis treatment.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/A108539

The primary drug segment dominated the global primary biliary cholangitis therapeutics market in 2022, representing over four-fifths of the revenue. It is expected to maintain its leading position throughout the forecast period due to the increasing adoption of primary drugs for treating primary biliary cholangitis (PBC). This segment is also projected to exhibit the highest compound annual growth rate (CAGR) of 7.3% from 2023 to 2032. This growth can be attributed to the intensified research and development efforts focused on primary drugs and their high effectiveness against PBC.

In 2022, North America emerged as the region with the highest revenue share in the global primary biliary cholangitis therapeutics market, capturing over two-fifths of the market revenue. This was attributed to its robust healthcare infrastructure, the presence of key industry players, and an increase in healthcare spending. However, the Asia-Pacific region is anticipated to experience the fastest compound annual growth rate (CAGR) of 8.5% from 2023 to 2032. It is expected to lead the market during the forecast period due to a surge in primary biliary cholangitis cases, unmet medical needs, and a large population base.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: -
ABC Farmaceutici S.p.a.
Alkem Laboratories Limited
AMAGEN INDIA LIFE SCIENCES
GENFIT
Intercept Pharmaceuticals, Inc.
Ipsen Pharma
Leeford Healthcare Ltd
Lupin
Sun Pharmaceutical Industries Ltd.
Zydus Lifesciences Limited

The report provides a detailed analysis of these key players in the global primary biliary cholangitis therapeutics market. These players have adopted different strategies such as acquisition, product launch, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 𝐢𝐧 𝐭𝐡𝐞 𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐁𝐢𝐥𝐢𝐚𝐫𝐲 𝐂𝐡𝐨𝐥𝐚𝐧𝐠𝐢𝐭𝐢𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

In May 2022, Intercept Pharmaceuticals, Inc. announced that it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, certain foreign subsidiaries and rights regarding Intercept's international operations, including a license to commercialize Ocaliva (obeticholic acid) outside of the U.S.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐀𝐧𝐚𝐥𝐲𝐬𝐭-https://www.alliedmarketresearch.com/connect-to-analyst/A108539

𝐑𝐞𝐜𝐞𝐧𝐭 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐢𝐧 𝐭𝐡𝐞 𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐁𝐢𝐥𝐢𝐚𝐫𝐲 𝐂𝐡𝐨𝐥𝐚𝐧𝐠𝐢𝐭𝐢𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Obeticholic Acid Tablets, 5mg and 10mg, a generic equivalent of Ocaliva Tablets, 5 mg, and 10 mg, of Intercept Pharmaceuticals, Inc. This product will be manufactured at Lupin's Nagpur facility in India.

𝐑𝐞𝐜𝐞𝐧𝐭 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐢𝐧 𝐭𝐡𝐞 𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐁𝐢𝐥𝐢𝐚𝐫𝐲 𝐂𝐡𝐨𝐥𝐚𝐧𝐠𝐢𝐭𝐢𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭

In December 2021, Ipsen and Genfit have entered a long-term strategic partnership in which Genfit has given Ipsen exclusive worldwide license to develop, manufacture, and commercialize its experimental late-stage treatment elafibranor, for people living with primary biliary cholangitis. The partnership also gives Ipsen access to future clinical programs led by Genfit and combines scientific expertise and proprietary technologies in liver disease of Genfit with development and commercialization capabilities of Ipsen.

𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐭𝐮𝐝𝐲

On the basis of drug type, the primary drug segment held the largest share in the primary biliary cholangitis therapeutics market analysis in 2022.

On the basis of distribution channel, the drugs stores and retail pharmacies dominated the market in 2022.

On the basis of region, Asia-Pacific is expected to witness the highest CAGR during the forecast period.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/primary-biliary-cholangitis-pbc-therapeutics-market-A108539

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.